The First Half of the Fiscal Year Ending March 31, 2022
Financial Results Presentation
November 4, 2021
SHIN NIPPON BIOMEDICAL LABORATORIES, LTD.
（TSE 1st Section: 2395）
Copyright© 2021 SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. All rights reserved.
Table of Contents
１．H1 FY2022/3 Overview | P. 2 |
２．Outline of Consolidated H1 Financial Results | P. 5 |
３．Business Topics | |
CRO (Preclinical) Business | P. 11 |
CRO (Clinical)/TR/Medipolis Business | P. 15 |
４．Q&A | P. 22 |
株式会社新日本科学 Copyright© 2021 SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. All rights reserved. 1
１．H1 FY2022/3 Overview
Representative Chairman and President, CEO and CHO Ryoichi Nagata, MD
株式会社新日本科学 Copyright© 2021 SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. All rights reserved. 2
Summary
1. H1 FY2022/3 Results
- Revenue and profits of CRO Business up substantially. Strong growth driven by the overall industry-wide trend of streamlining operations and accelerating R&D activities
- Efforts on "time-value creation" that help maximize benefits in clients starting to gain traction
- Set new record-high strong orders received in H1
２．Full-year Forecasts and Future Direction
- Revise up full-year guidance based on H1 results and current business environments
- Expect favorable business environment for CRO Business to continue in H2
-
Medium- to long-term management perspective is a key to achieve our goal of becoming
"DANTOTSU" (best by far) CRO in the industry.
３．Initiatives to Enhance Corporate Value : SDGs/ESG
- Undertake "visualization" of corporate activities through enhanced disclosure and IR/PR activities
- Set SDGs Committee and publish first sustainability report
- Continue to enhance corporate value as industry leader in initiatives for SDGs/ESG
株式会社新日本科学 Copyright© 2021 SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. All rights reserved. 3
Initiatives to Enhance Corporate Value : SDGs/ESG
- Undertaking "visualization" of corporate activities through enhanced disclosure and IR/PR activities
- Set SDGs Committee and published first sustainability report
- Continue to enhance corporate value as industry leader in initiatives for SDGs/ESG
＜Materiality and Sustainability Focus at SNBL Group＞
■ Forest in Medipolis Ibusuki, Ibusuki City,
Kagoshima Pref.
＜External Recognition＞
■ Geothermal power plant in Medipolis Ibusuki
Source："Sustainability Report 2021"（https://www2.tse.or.jp/disc/23950/140120211025416124.pdf）
株式会社新日本科学 Copyright© 2021 SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. All rights reserved. 4
This is an excerpt of the original content. To continue reading it, access the original document here.